This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

R1 RCM Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

R1 RCM yıllık ortalama 11.1% oranında kazançlarını artırırken, Healthcare sektöründe kazançlar growing at 7.2% annual. Gelirler yılda ortalama 16.9% oranında büyüyor .

Anahtar bilgiler

11.1%

Kazanç büyüme oranı

18.8%

EPS büyüme oranı

Healthcare Sektör Büyümesi	15.7%
Gelir büyüme oranı	16.9%
Özkaynak getirisi	-2.2%
Net Marj	-2.5%
Son Kazanç Güncellemesi	30 Sep 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

R1 RCM nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

DB:6HL0 Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri
30 Sep 24	2,464	-61	241
30 Jun 24	2,380	-40	233
31 Mar 24	2,313	-33	237
31 Dec 23	2,254	3	220
30 Sep 23	2,212	-35	219
30 Jun 23	2,135	-65	222
31 Mar 23	1,966	-91	190
31 Dec 22	1,806	-63	173
30 Sep 22	1,672	-1	152
30 Jun 22	1,556	45	127
31 Mar 22	1,518	91	126
31 Dec 21	1,475	-505	122
30 Sep 21	1,404	-495	116
30 Jun 21	1,332	-512	108
31 Mar 21	1,293	-526	103
31 Dec 20	1,270	47	101
30 Sep 20	1,256	14	102
30 Jun 20	1,250	16	105
31 Mar 20	1,231	3	108
31 Dec 19	1,186	-9	105
30 Sep 19	1,135	-22	106
30 Jun 19	1,084	-42	107
31 Mar 19	997	-41	104
31 Dec 18	869	-64	98
30 Sep 18	746	-99	84
30 Jun 18	619	-88	69
31 Mar 18	510	-92	59
31 Dec 17	450	-76	56
30 Sep 17	416	-28	60
30 Jun 17	418	-3	65
31 Mar 17	327	-36	71
31 Dec 16	593	65	74
30 Sep 16	555	68	73
30 Jun 16	445	17	75
31 Mar 16	458	35	78
31 Dec 15	117	-84	75
30 Sep 15	96	-107	77
30 Jun 15	171	-65	72
31 Mar 15	208	-55	71
31 Dec 14	210	-80	76
30 Sep 14	247	-56	70
30 Jun 14	174	-103	76
31 Mar 14	490	102	75
31 Dec 13	505	130	80

Kaliteli Kazançlar: 6HL0 şu anda kârlı değil.

Büyüyen Kar Marjı: 6HL0 şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 6HL0 kârlı değildir, ancak son 5 yılda zararlarını yılda 11.1% oranında azaltmıştır.

Büyüme Hızlandırma: 6HL0 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: 6HL0 kârlı olmadığından, geçmiş yıl kazanç büyümesinin Healthcare sektörüyle ( 40.5% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: 6HL0 hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -2.18% ) sahiptir.

This company listing is no longer active

R1 RCM Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Third quarter 2024 earnings released: US$0.047 loss per share (vs US$0.003 profit in 3Q 2023)

Second quarter 2024 earnings released: US$0.018 loss per share (vs US$0.002 loss in 2Q 2023)

R1 RCM Inc. to Report Q2, 2024 Results on Aug 07, 2024

First quarter 2024 earnings released: US$0.083 loss per share (vs US$0.004 profit in 1Q 2023)

R1 RCM Inc. to Report Q1, 2024 Results on May 08, 2024

Full year 2023 earnings released: EPS: US$0.008 (vs US$0.18 loss in FY 2022)

Recent updates

R1 RCM Inc.(NasdaqGM:RCM) dropped from NASDAQ Composite Index

R1 RCM Inc.(NasdaqGS:RCM) dropped from S&P Health Care Services Select Industry Index

Third quarter 2024 earnings released: US$0.047 loss per share (vs US$0.003 profit in 3Q 2023)

R1 RCM Inc. Provides Unaudited Preliminary Financial Guidance for the Fiscal Quarter Ended September 30, 2024

Second quarter 2024 earnings released: US$0.018 loss per share (vs US$0.002 loss in 2Q 2023)

TowerBrook Capital Partners L.P. and Clayton, Dubilier & Rice, LLC agreed to acquire remaining 64% stake in R1 RCM Inc. (NasdaqGS:RCM) from TowerBrook Capital Partners L.P. and others for $6.3 billion.

R1 RCM Inc. to Report Q2, 2024 Results on Aug 07, 2024

R1 RCM Inc. Revises Earnings Guidance for the Year 2024

First quarter 2024 earnings released: US$0.083 loss per share (vs US$0.004 profit in 1Q 2023)

R1 RCM Inc., Annual General Meeting, May 22, 2024

R1 RCM Inc. to Report Q1, 2024 Results on May 08, 2024

R1 RCM Inc. Provides Earnings Guidance for the Fiscal Year 2024

New minor risk - Earnings quality

New Mountain Partners V (AIV-D), L.P. and New Mountain Investments V, L.L.C., managed by New Mountain Capital, L.L.C. submits a non-binding proposal to acquire remaining 67.56906% stake in R1 RCM Inc. (NasdaqGS:RCM) from TowerBrook Investors, Ltd and others for approximately $4 billion.

Full year 2023 earnings released: EPS: US$0.008 (vs US$0.18 loss in FY 2022)

Coliseum Capital Issues an Open Letter to the Board of R1 RCM

R1 RCM Inc. Appoints Pamela L. Spikner as Principal Accounting Officer

R1 RCM Inc. (NasdaqGS:RCM) completed the acquisition of Acclara Solutions, LLC from Providence St. Joseph Health for $680 million.

R1 RCM Inc. to Report Q4, 2023 Results on Feb 27, 2024

R1 RCM Inc. Appoints Clay Ashdown as Director

R1 RCM Inc. (NasdaqGS:RCM) entered into the Purchase Agreement to acquire Acclara Solutions, LLC from Providence St. Joseph Health.

R1 RCM Inc. (NasdaqGS:RCM) entered into the Purchase Agreement to acquire Acclara Solutions, LLC from Providence St. Joseph Health.

R1 RCM Receives Notice Of Filing Delinquency from Nasdaq

R1 RCM Receives Notice Of Filing Delinquency from Nasdaq

R1 RCM Inc. announced delayed 10-Q filing

R1 RCM Inc. Provides Revenue Guidance for the Year 2023

Third quarter 2023 earnings released: EPS: US$0.003 (vs US$0.071 loss in 3Q 2022)

R1 RCM Inc. Announces Janie Wade Resigns from its Board of Directors

New minor risk - Share price stability

R1 RCM Inc. to Report Q3, 2023 Results on Nov 02, 2023

Now 21% undervalued after recent price drop

Second quarter 2023 earnings released: EPS: US$0.001 (vs US$0.069 loss in 2Q 2022)

R1 RCM Inc. Provides Earnings Guidance for the Year of 2023

R1 RCM Inc. to Report Q2, 2023 Results on Aug 02, 2023

Senior VP recently sold €452k worth of stock

President recently sold €298k worth of stock

R1 RCM Inc. Provides Earnings Guidance for the Year 2023

First quarter 2023 earnings released: EPS: US$0.001 (vs US$0.10 in 1Q 2022)

CEO & Director recently bought €937k worth of stock

Full year 2022 earnings released: US$0.16 loss per share (vs US$1.86 loss in FY 2021)

R1 RCM Inc. Provides Earnings Guidance for the Fiscal Year 2023

R1 RCM Inc. to Report Q4, 2022 Results on Feb 16, 2023

R1 RCM Inc. Announces Chief Financial Officer Changes

R1 RCM Inc. Appoints Janie Wade as a Director of the Company, Effective January 1, 2023

R1 RCM Inc. Announces Retirement of Albert Zimmerli from the Board of Directors, Effective January 1, 2023

Third quarter 2022 earnings released: US$0.071 loss per share (vs US$0.061 profit in 3Q 2021)

R1 RCM Inc. Provides Earnings Guidance for the Year 2022

R1 RCM Inc. to Report Q3, 2022 Results on Nov 08, 2022

Key Executive recently sold €996k worth of stock

R1 RCM Inc. Appoints Brian Dean as Director

Independent Director recently sold €266k worth of stock

Second quarter 2022 earnings released: US$0.069 loss per share (vs US$0.069 profit in 2Q 2021)

R1 RCM Inc. Provides Revenue Guidance for the Full Year of 2022

R1 RCM Inc. to Report Q2, 2022 Results on Aug 03, 2022

New Mountain Capital Engages in Discussions with R1 RCM Inc

R1 RCM Inc. Revises Revenue Guidance for the Year 2022

R1 RCM Inc. Announces Committee Changes

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin